

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person* <u>EVNIN LUKE</u> (Last) (First) (Middle) <u>C/O MPM BIOIMPACT LLC</u> <u>399 BOYLSTON STREET, SUITE 1100</u> (Street) <u>BOSTON MA 02116</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Werewolf Therapeutics, Inc. [HOWL]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>01/05/2026</u>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	01/05/2026		s ⁽¹⁾		18,378 ⁽²⁾	D	\$0.64 ⁽³⁾	2,453,919	I	See Footnotes ⁽⁴⁾⁽⁵⁾
Common Stock	01/06/2026		s ⁽¹⁾		40,761 ⁽⁶⁾	D	\$0.65 ⁽⁷⁾	2,413,158	I	See Footnotes ⁽⁴⁾⁽⁸⁾
Common Stock	01/07/2026		s ⁽¹⁾		11,915 ⁽⁹⁾	D	\$0.64 ⁽¹⁰⁾	2,401,243	I	See Footnotes ⁽⁴⁾⁽¹¹⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					

Explanation of Responses:

- Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.
- The shares were sold as follows: 1,966 by MPM Asset Management LLC ("AM LLC"), 12,420 by MPM BioVentures 2014, L.P. ("BV 2014"), 828 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 429 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 2,735 by MPM Oncology Innovations Fund, L.P. ("MPM OIF").
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$0.63435 to \$0.6549 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
- The shares are held as follows: 262,868 by AM LLC, 1,659,794 by BV 2014, 110,705 by BV 2014(B), 57,125 by AM BV2014 and 363,427 by MPM OIF.
- The shares were sold as follows: 4,361 by AM LLC, 27,548 by BV 2014, 1,837 by BV 2014(B), 948 by AM BV2014 and 6,067 by MPM OIF.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$0.64 to \$0.6599 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The shares are held as follows: 258,507 by AM LLC, 1,632,246 by BV 2014, 108,868 by BV 2014(B), 56,177 by AM BV2014 and 357,360 by MPM OIF.
- The shares were sold as follows: 1,275 by AM LLC, 8,053 by BV 2014, 537 by BV 2014(B), 277 by AM BV2014 and 1,773 by MPM OIF.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$0.6276 to \$0.6598 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The shares are held as follows: 257,232 by AM LLC, 1,624,193 by BV 2014, 108,331 by BV 2014(B), 55,900 by AM BV2014 and 355,587 by MPM OIF.

/s/ Luke Evnin

01/07/2026

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

**** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).**

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.